Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)

{ 'indexed': {'date-parts': [[2023, 8, 11]], 'date-time': '2023-08-11T23:56:51Z', 'timestamp': 1691798211211}, 'reference-count': 70, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2022, 6, 29]], 'date-time': '2022-06-29T00:00:00Z', 'timestamp': 1656460800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2022, 6, 29]], 'date-time': '2022-06-29T00:00:00Z', 'timestamp': 1656460800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [ { 'name': 'Ohio State University Center for Clinical and Translational Science', 'award': ['CTSA Grant UL1TR002733']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Resveratrol is a polyphenol that has been well ' 'studied and has demonstrated anti-viral and anti-inflammatory properties that might mitigate ' 'the effects of COVID-19. Outpatients (N\u2009=\u2009105) were recruited from central Ohio in ' 'late 2020. Participants were randomly assigned to receive placebo or resveratrol. Both groups ' 'received a single dose of Vitamin D3 which was used as an adjunct. The primary outcome ' 'measure was hospitalization within 21\xa0days of symptom onset; secondary measures were ER ' 'visits, incidence of pneumonia, and incidence of pulmonary embolism. Five patients chose not ' 'to participate after randomization. Twenty-one-day outcome was determined of all one hundred ' 'participants (mean [SD] age 55.6 [8.8] years; 61% female). There were no clinically ' 'significant adverse events attributed to resveratrol. Outpatients in this phase 2 study ' 'treated with resveratrol had a lower incidence compared to placebo of: hospitalization (2% ' 'vs. 6%, RR 0.33, 95% CI 0.04–3.10), COVID-19 related ER visits (8% vs. 14%, RR 0.57, 95% CI ' '0.18–1.83), and pneumonia (8% vs. 16%, RR 0.5, 95% CI 0.16–1.55). One patient (2%) in each ' 'group developed pulmonary embolism (RR 1.00, 95% CI: 0.06–15.55). This underpowered study was ' 'limited by small sample size and low incidence of primary adverse events consequently the ' 'results are statistically similar between treatment arms. A larger trial could determine ' 'efficacy.</jats:p><jats:p>Trial Registrations: ClinicalTrials.gov NCT04400890 26/05/2020; FDA ' 'IND #150033 05/05/2020.</jats:p>', 'DOI': '10.1038/s41598-022-13920-9', 'type': 'journal-article', 'created': {'date-parts': [[2022, 6, 29]], 'date-time': '2022-06-29T15:09:31Z', 'timestamp': 1656515371000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 14, 'title': 'Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient ' 'treatment of mild coronavirus disease (COVID-19)', 'prefix': '10.1038', 'volume': '12', 'author': [ {'given': 'Marvin R.', 'family': 'McCreary', 'sequence': 'first', 'affiliation': []}, {'given': 'Patrick M.', 'family': 'Schnell', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dale A.', 'family': 'Rhoda', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 6, 29]]}, 'reference': [ { 'key': '13920_CR1', 'doi-asserted-by': 'publisher', 'first-page': '6064', 'DOI': '10.2174/13816128113199990407', 'volume': '19', 'author': 'J Tomé-Carneiro', 'year': '2013', 'unstructured': 'Tomé-Carneiro, J. et al. Resveratrol and clinical trials: The crossroad ' 'from in vitro studies to human evidence. Curr. Pharm. Des. 19, 6064–6093 ' '(2013).', 'journal-title': 'Curr. Pharm. Des.'}, { 'key': '13920_CR2', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1155/2015/184241', 'volume': '2015', 'author': 'Y Abba', 'year': '2015', 'unstructured': 'Abba, Y., Hassim, H., Hamzah, H. & Noordin, M. M. Antiviral activity of ' 'resveratrol against human and animal viruses. Adv. Virol. 2015, 1 ' '(2015).', 'journal-title': 'Adv. Virol.'}, { 'key': '13920_CR3', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1016/j.ymben.2015.08.007', 'volume': '32', 'author': 'M Li', 'year': '2015', 'unstructured': 'Li, M. et al. De novo production of resveratrol from glucose or ethanol ' 'by engineered Saccharomyces cerevisiae. Metab. Eng. 32, 1–11 (2015).', 'journal-title': 'Metab. Eng.'}, { 'key': '13920_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1080/07391102.2020.1762743', 'volume': '39', 'author': 'HM Wahedi', 'year': '2020', 'unstructured': 'Wahedi, H. M., Ahmad, S. & Abbasi, S. W. Stilbene-based natural ' 'compounds as promising drug candidates against COVID-19. J. Biomol. ' 'Struct. Dyn. 39, 1–10 (2020).', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '13920_CR5', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1080/07391102.2020.1796811', 'volume': '39', 'author': 'P Pandey', 'year': '2020', 'unstructured': 'Pandey, P. et al. Targeting SARS-CoV-2 spike protein of COVID-19 with ' 'naturally occurring phytochemicals: an in silico study for drug ' 'development. Null 39, 1–11. ' 'https://doi.org/10.1080/07391102.2020.1796811 (2020).', 'journal-title': 'Null'}, { 'key': '13920_CR6', 'unstructured': 'Ranjbar, A., Jamshidi, M. & Torabi, S. Molecular modelling of the ' 'antiviral action of Resveratrol derivatives against the activity of two ' 'novel SARS CoV-2 and 2019-nCoV receptors. Eur. Rev. Med. Pharmacol. Sci. ' '7834–7844 (2020).'}, { 'key': '13920_CR7', 'doi-asserted-by': 'publisher', 'unstructured': 'Mishra, A., Pathak, Y. & Tripathi, V. Natural compounds as potential ' 'inhibitors of novel coronavirus (COVID-19) main protease: An in silico ' 'study. Res. Square. Preprint (2020) ' 'https://doi.org/10.21203/rs.3.rs-22839/v2.', 'DOI': '10.21203/rs.3.rs-22839/v2'}, { 'key': '13920_CR8', 'doi-asserted-by': 'publisher', 'first-page': '657', 'DOI': '10.1038/s41586-020-2601-5', 'volume': '587', 'author': 'D Shin', 'year': '2020', 'unstructured': 'Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread ' 'and innate immunity. Nature 587, 657–622 (2020).', 'journal-title': 'Nature'}, { 'key': '13920_CR9', 'doi-asserted-by': 'crossref', 'unstructured': 'Rathnayake, A., Zheng, J., Kim, Y., & et al. 3C-like protease inhibitors ' 'block coronavirus replication in vitro and improve survival in ' 'MERS-CoV-infected mice. Sci. Transl. Med. 12, (2020).', 'DOI': '10.1126/scitranslmed.abc5332'}, { 'key': '13920_CR10', 'doi-asserted-by': 'publisher', 'unstructured': 'El-Aziz, N. M. A., Shehata, M. G., Awad, O. M. E. & El-Sohaimy, S. A. ' 'Inhibition of COVID-19 RNA-dependent RNA polymerase by natural bioactive ' 'compounds: Molecular docking analysis. Res. Square. Preprint (2020). ' 'https://doi.org/10.21203/rs.3.rs-25850/v1.', 'DOI': '10.21203/rs.3.rs-25850/v1'}, { 'key': '13920_CR11', 'doi-asserted-by': 'publisher', 'first-page': '127', 'DOI': '10.1007/s13596-018-0311-4', 'volume': '18', 'author': 'B Maity', 'year': '2018', 'unstructured': 'Maity, B., Bora, M. & Sur, D. An effect of combination of resveratrol ' 'with vitamin D3 on modulation of proinflammatory cytokines in diabetic ' 'nephropathy induces rat. Orient. Pharm. Exp. Med. 18, 127–138 (2018).', 'journal-title': 'Orient. Pharm. Exp. Med.'}, { 'key': '13920_CR12', 'doi-asserted-by': 'publisher', 'first-page': '987', 'DOI': '10.1182/blood-2002-11-3550', 'volume': '102', 'author': 'Z Estrov', 'year': '2003', 'unstructured': 'Estrov, Z. et al. Resveratrol blocks interleukin-1beta-induced ' 'activation of the nuclear transcription factor NF-kappaB, inhibits ' 'proliferation, causes S-phase arrest, and induces apoptosis of acute ' 'myeloid leukemia cells. Blood 102, 987–995 (2003).', 'journal-title': 'Blood'}, { 'key': '13920_CR13', 'doi-asserted-by': 'publisher', 'first-page': '471', 'DOI': '10.1016/j.bbrc.2008.02.034', 'volume': '369', 'author': 'J Zhu', 'year': '2008', 'unstructured': 'Zhu, J., Yong, W. & Wu, X. Anti-inflammatory effect of resveratrol on ' 'TNF-alpha-induced MCP-1 expression in adipocytes. Biochem. Biophys. Res. ' 'Commun. 369, 471–477 (2008).', 'journal-title': 'Biochem. Biophys. Res. Commun.'}, { 'key': '13920_CR14', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1016/j.ejphar.2018.08.014', 'volume': '836', 'author': 'J Sun', 'year': '2018', 'unstructured': 'Sun, J. et al. Suppression of TLR4 activation by resveratrol is ' 'associated with STAT3 and Akt inhibition in oxidized low-density ' 'lipoprotein-activated platelets. Eur. J. Pharmacol. 836, 1–10 (2018).', 'journal-title': 'Eur. J. Pharmacol.'}, { 'key': '13920_CR15', 'doi-asserted-by': 'publisher', 'first-page': '810', 'DOI': '10.1016/S0891-5849(02)01430-2', 'volume': '34', 'author': 'S Shigematsu', 'year': '2003', 'unstructured': 'Shigematsu, S. et al. Resveratrol, a red wine constituent polyphenol, ' 'prevents superoxide-dependent inflammatory responses induced by ' 'ischemia/reperfusion, platelet-activating factor, or oxidants. Free ' 'Radical Biol. Med. 34, 810–817 (2003).', 'journal-title': 'Free Radical Biol. Med.'}, { 'key': '13920_CR16', 'doi-asserted-by': 'publisher', 'first-page': '16102', 'DOI': '10.3390/molecules191016102', 'volume': '19', 'author': 'N Xia', 'year': '2014', 'unstructured': 'Xia, N., Förstermann, U. & Li, H. Resveratrol and endothelial nitric ' 'oxide. Molecules 19, 16102–16121 (2014).', 'journal-title': 'Molecules'}, { 'key': '13920_CR17', 'doi-asserted-by': 'publisher', 'first-page': '1966', 'DOI': '10.1128/JVI.79.3.1966-1969.2005', 'volume': '79', 'author': 'S Åkerström', 'year': '2005', 'unstructured': 'Åkerström, S. et al. Nitric oxide inhibits the replication cycle of ' 'severe acute respiratory syndrome coronavirus. J. Virol. 79, 1966–1969 ' '(2005).', 'journal-title': 'J. Virol.'}, { 'key': '13920_CR18', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1016/j.virol.2009.09.007', 'volume': '395', 'author': 'S Åkerström', 'year': '2009', 'unstructured': 'Åkerström, S., Gunalan, V., Keng, C. T., Tan, Y.-J. & Mirazimi, A. Dual ' 'effect of nitric oxide on SARS-CoV replication: Viral RNA production and ' 'palmitoylation of the S protein are affected. Virology 395, 1–9 (2009).', 'journal-title': 'Virology'}, { 'key': '13920_CR19', 'first-page': '689', 'volume': '68', 'author': 'X Ren', 'year': '2013', 'unstructured': 'Ren, X. et al. Resveratrol inhibits NF-kB signaling through suppression ' 'of p65 and IkappaB kinase activities. Pharmazie 68, 689 (2013).', 'journal-title': 'Pharmazie'}, { 'key': '13920_CR20', 'doi-asserted-by': 'publisher', 'first-page': '129', 'DOI': '10.1136/ard.2011.149831', 'volume': '71', 'author': 'G Xuzhu', 'year': '2021', 'unstructured': 'Xuzhu, G. et al. Resveratrol modulates murine collagen-induced arthritis ' 'by inhibiting Th17 and B-cell function. Ann. Rheum. Dis. 71, 129–135 ' '(2021).', 'journal-title': 'Ann. Rheum. Dis.'}, { 'key': '13920_CR21', 'doi-asserted-by': 'publisher', 'first-page': '1558', 'DOI': '10.1021/acsinfecdis.0c00288', 'volume': '6', 'author': 'A Polonikov', 'year': '2020', 'unstructured': 'Polonikov, A. Endogenous deficiency of glutathione as the most likely ' 'cause of serious manifestations and death in COVID-19 patients. ACS ' 'Infectious Diseases 6, 1558–1562 (2020).', 'journal-title': 'ACS Infectious Diseases'}, { 'key': '13920_CR22', 'doi-asserted-by': 'publisher', 'first-page': 'L478', 'DOI': '10.1152/ajplung.00361.2007', 'volume': '294', 'author': 'A Kode', 'year': '2008', 'unstructured': 'Kode, A. et al. Resveratrol induces glutathione synthesis by activation ' 'of Nrf2 and protects against cigarette smoke-mediated oxidative stress ' 'in human lung epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. ' '294, L478–L488 (2008).', 'journal-title': 'Am. J. Physiol. Lung Cell Mol. Physiol.'}, { 'key': '13920_CR23', 'volume': '30', 'author': 'RI Horowitz', 'year': '2020', 'unstructured': 'Horowitz, R. I., Freeman, P. R. & Bruzzese, J. Efficacy of glutathione ' 'therapy in relieving dyspnea associated with COVID-19 pneumonia: A ' 'report of 2 cases. Respir. Med. Case. Rep. 30, 101063 (2020).', 'journal-title': 'Respir. Med. Case. Rep.'}, { 'key': '13920_CR24', 'doi-asserted-by': 'publisher', 'first-page': '875', 'DOI': '10.1038/nm1267', 'volume': '11', 'author': 'K Kuba', 'year': '2005', 'unstructured': 'Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) ' 'in SARS coronavirus-induced lung injury. Nat. Med. 11, 875–879 (2005).', 'journal-title': 'Nat. Med.'}, { 'key': '13920_CR25', 'doi-asserted-by': 'publisher', 'first-page': '1033', 'DOI': '10.1016/S0140-6736(20)30628-0', 'volume': '395', 'author': 'P Mehta', 'year': '2020', 'unstructured': 'Mehta, P. et al. COVID-19: Consider cytokine storm syndromes and ' 'immunosuppression. Lancet 395, 1033–1034 (2020).', 'journal-title': 'Lancet'}, { 'key': '13920_CR26', 'doi-asserted-by': 'publisher', 'first-page': '821', 'DOI': '10.1038/nm0805-821', 'volume': '11', 'author': 'J Nicholls', 'year': '2005', 'unstructured': 'Nicholls, J. & Peiris, M. Good ACE, bad ACE do battle in lung injury, ' 'SARS. Nat. Med. 11, 821–822 (2005).', 'journal-title': 'Nat. Med.'}, { 'key': '13920_CR27', 'doi-asserted-by': 'publisher', 'first-page': '19840', 'DOI': '10.1038/srep19840', 'volume': '6', 'author': 'H Gu', 'year': '2016', 'unstructured': 'Gu, H. et al. Angiotensin-converting enzyme 2 inhibits lung injury ' 'induced by respiratory syncytial virus. Sci. Rep. 6, 19840–19840 (2016).', 'journal-title': 'Sci. Rep.'}, { 'key': '13920_CR28', 'doi-asserted-by': 'publisher', 'first-page': '6017', 'DOI': '10.1096/fj.202000782', 'volume': '34', 'author': 'T Yan', 'year': '2020', 'unstructured': 'Yan, T., Xiao, R. & Lin, G. Angiotensin-converting enzyme 2 in severe ' 'acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged ' 'sword?. FASEB J. 34, 6017–6026 (2020).', 'journal-title': 'FASEB J.'}, { 'key': '13920_CR29', 'doi-asserted-by': 'publisher', 'first-page': '2195', 'DOI': '10.1161/ATVBAHA.117.310129', 'volume': '37', 'author': 'CS Moran', 'year': '2017', 'unstructured': 'Moran, C. S. et al. Resveratrol inhibits growth of experimental ' 'abdominal aortic aneurysm associated with upregulation of ' 'angiotensin-converting enzyme 2. Arterioscler. Thromb. Vasc. Biol. 37, ' '2195–2203 (2017).', 'journal-title': 'Arterioscler. Thromb. Vasc. Biol.'}, { 'key': '13920_CR30', 'doi-asserted-by': 'publisher', 'first-page': '112', 'DOI': '10.1038/nature03712', 'volume': '436', 'author': 'Y Imai', 'year': '2005', 'unstructured': 'Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe ' 'acute lung failure. Nature 436, 112–116 (2005).', 'journal-title': 'Nature'}, { 'key': '13920_CR31', 'doi-asserted-by': 'publisher', 'first-page': 'E830', 'DOI': '10.1152/ajpendo.00150.2020', 'volume': '318', 'author': 'JR Horne', 'year': '2020', 'unstructured': 'Horne, J. R. & Vohl, M.-C. Biological plausibility for interactions ' 'between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity. ' 'Am. J. Physiol. Endocrinol. Metab. 318, E830–E833 (2020).', 'journal-title': 'Am. J. Physiol. Endocrinol. Metab.'}, { 'key': '13920_CR32', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.2174/187153032001191213111933', 'volume': '20', 'author': 'T Magrone', 'year': '2020', 'unstructured': 'Magrone, T., Magrone, M. & Jirillo, E. Focus on receptors for ' 'coronaviruses with special reference to angiotensin-converting enzyme 2 ' 'as a potential drug target - a perspective. Endocr. Metab. Immune ' 'Disord. Drug Targets 20, 1–11 (2020).', 'journal-title': 'Endocr. Metab. Immune Disord. Drug Targets'}, { 'key': '13920_CR33', 'doi-asserted-by': 'publisher', 'first-page': '144', 'DOI': '10.1186/s12879-017-2253-8', 'volume': '17', 'author': 'S-C Lin', 'year': '2017', 'unstructured': 'Lin, S.-C. et al. Effective inhibition of MERS-CoV infection by ' 'resveratrol. BMC Infect. Dis. 17, 144 (2017).', 'journal-title': 'BMC Infect. Dis.'}, { 'key': '13920_CR34', 'doi-asserted-by': 'publisher', 'first-page': 'e1007390', 'DOI': '10.1371/journal.ppat.1007390', 'volume': '14', 'author': 'J Olejnik', 'year': '2018', 'unstructured': 'Olejnik, J., Hume, A. J. & Mühlberger, E. Toll-like receptor 4 in acute ' 'viral infection: Too much of a good thing. PLoS Pathog. 14, e1007390 ' '(2018).', 'journal-title': 'PLoS Pathog.'}, { 'key': '13920_CR35', 'unstructured': 'Conti, P. et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) ' 'and lung inflammation by COVID-19: anti-inflammatory strategies. J. ' 'Biol. Regulat. Homeostatic Agents 34, (2020).'}, { 'key': '13920_CR36', 'doi-asserted-by': 'publisher', 'unstructured': 'Patterson, B. K. et al. Disruption of the CCL5/RANTES-CCR5 Pathway ' 'Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical ' 'COVID-19. https://doi.org/10.1101/2020.05.02.20084673 (2020).', 'DOI': '10.1101/2020.05.02.20084673'}, { 'key': '13920_CR37', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1016/j.virusres.2007.02.007', 'volume': '128', 'author': 'W Wang', 'year': '2007', 'unstructured': 'Wang, W. et al. Up-regulation of IL-6 and TNF-α induced by ' 'SARS-coronavirus spike protein in murine macrophages via NF-κB pathway. ' 'Virus Res. 128, 1–8 (2007).', 'journal-title': 'Virus Res.'}, { 'key': '13920_CR38', 'doi-asserted-by': 'publisher', 'first-page': '3591', 'DOI': '10.2147/DDDT.S148868', 'volume': '11', 'author': 'X Zhu', 'year': '2017', 'unstructured': 'Zhu, X., Lei, X. & Dong, W. Resveratrol as a potential therapeutic drug ' 'for respiratory system diseases. Drug Des. Dev. Ther. 11, 3591–3598 ' '(2017).', 'journal-title': 'Drug Des. Dev. Ther.'}, { 'key': '13920_CR39', 'doi-asserted-by': 'publisher', 'first-page': '942', 'DOI': '10.1136/thorax.58.11.942', 'volume': '58', 'author': 'SV Culpitt', 'year': '2003', 'unstructured': 'Culpitt, S. V. et al. Inhibition by red wine extract, resveratrol, of ' 'cytokine release by alveolar macrophages in COPD. Thorax 58, 942–946 ' '(2003).', 'journal-title': 'Thorax'}, { 'key': '13920_CR40', 'doi-asserted-by': 'publisher', 'first-page': '913', 'DOI': '10.1128/JVI.02576-13', 'volume': '88', 'author': 'ML DeDiego', 'year': '2014', 'unstructured': 'DeDiego, M. L. et al. Inhibition of NF-κB-mediated inflammation in ' 'severe acute respiratory syndrome coronavirus-infected mice increases ' 'survival. J. Virol. 88, 913–924 (2014).', 'journal-title': 'J. Virol.'}, { 'key': '13920_CR41', 'doi-asserted-by': 'publisher', 'first-page': '2644', 'DOI': '10.1111/jcmm.13542', 'volume': '22', 'author': 'H Alghetaa', 'year': '2018', 'unstructured': 'Alghetaa, H. et al. Resveratrol protects mice against SEB-induced acute ' 'lung injury and mortality by miR-193a modulation that targets TGF-β ' 'signalling. J. Cell Mol. Med. 22, 2644–2655 (2018).', 'journal-title': 'J. Cell Mol. Med.'}, { 'key': '13920_CR42', 'doi-asserted-by': 'publisher', 'first-page': '130', 'DOI': '10.1016/j.biopha.2016.09.020', 'volume': '84', 'author': 'L Jiang', 'year': '2016', 'unstructured': 'Jiang, L. et al. Resveratrol ameliorates LPS-induced acute lung injury ' 'via NLRP3 inflammasome modulation. Biomed. Pharmacother. 84, 130–138 ' '(2016).', 'journal-title': 'Biomed. Pharmacother.'}, { 'key': '13920_CR43', 'doi-asserted-by': 'publisher', 'first-page': '773', 'DOI': '10.1586/ers.10.71', 'volume': '4', 'author': 'H Chen', 'year': '2010', 'unstructured': 'Chen, H., Bai, C. & Wang, X. The value of the lipopolysaccharide-induced ' 'acute lung injury model in respiratory medicine. Expert Rev. Respir. ' 'Med. 4, 773–783 (2010).', 'journal-title': 'Expert Rev. Respir. Med.'}, { 'key': '13920_CR44', 'doi-asserted-by': 'crossref', 'unstructured': 'Shah, A. Novel coronavirus-induced NLRP3 inflammasome activation: A ' 'potential drug target in the treatment of COVID-19. Front. Immunol. 11, ' '(2020).', 'DOI': '10.3389/fimmu.2020.01021'}, { 'key': '13920_CR45', 'doi-asserted-by': 'publisher', 'first-page': '137', 'DOI': '10.1016/j.ijcard.2020.04.009', 'volume': '312', 'author': 'J-Z Wang', 'year': '2020', 'unstructured': 'Wang, J.-Z., Zhang, R.-Y. & Bai, J. An anti-oxidative therapy for ' 'ameliorating cardiac injuries of critically ill COVID-19-infected ' 'patients. Int. J. Cardiol. 312, 137–138 (2020).', 'journal-title': 'Int. J. Cardiol.'}, { 'key': '13920_CR46', 'doi-asserted-by': 'publisher', 'first-page': '457', 'DOI': '10.3390/v10090457', 'volume': '10', 'author': 'X Zhao', 'year': '2018', 'unstructured': 'Zhao, X. et al. Antiviral effect of resveratrol in piglets infected with ' 'virulent pseudorabies virus. Viruses 10, 457 (2018).', 'journal-title': 'Viruses'}, { 'key': '13920_CR47', 'doi-asserted-by': 'publisher', 'first-page': '102571', 'DOI': '10.1016/j.autrev.2020.102571', 'volume': '19', 'author': 'P Fagone', 'year': '2020', 'unstructured': 'Fagone, P. et al. Transcriptional landscape of SARS-CoV-2 infection ' 'dismantles pathogenic pathways activated by the virus, proposes unique ' 'sex-specific differences and predicts tailored therapeutic strategies. ' 'Autoimmun. Rev. 19, 102571–102571 (2020).', 'journal-title': 'Autoimmun. Rev.'}, { 'key': '13920_CR48', 'doi-asserted-by': 'publisher', 'first-page': '1719', 'DOI': '10.1086/429694', 'volume': '191', 'author': 'AT Palamara', 'year': '2005', 'unstructured': 'Palamara, A. T. et al. Inhibition of influenza a virus replication by ' 'resveratrol. J. Infect. Dis. 191, 1719–1729 (2005).', 'journal-title': 'J. Infect. Dis.'}, { 'key': '13920_CR49', 'doi-asserted-by': 'publisher', 'first-page': '13061', 'DOI': '10.1128/JVI.05869-11', 'volume': '85', 'author': 'N Zang', 'year': '2011', 'unstructured': 'Zang, N. et al. Resveratrol-mediated gamma interferon reduction prevents ' 'airway inflammation and airway hyperresponsiveness in respiratory ' 'syncytial virus-infected immunocompromised mice. J. Virol. 85, ' '13061–13068 (2011).', 'journal-title': 'J. Virol.'}, { 'key': '13920_CR50', 'doi-asserted-by': 'publisher', 'first-page': '988', 'DOI': '10.3390/nu12040988', 'volume': '12', 'author': 'W Grant', 'year': '2020', 'unstructured': 'Grant, W. et al. Evidence that vitamin D supplementation could reduce ' 'risk of influenza and COVID-19 infections and deaths. Nutrients 12, 988 ' '(2020).', 'journal-title': 'Nutrients'}, { 'key': '13920_CR51', 'doi-asserted-by': 'publisher', 'first-page': '1038', 'DOI': '10.1007/s12603-020-1517-y', 'volume': '24', 'author': 'MT Aslan', 'year': '2020', 'unstructured': 'Aslan, M. T., Aslan, İÖ. & Özdemir, Ö. Is vitamin D one of the key ' 'elements in COVID-19 days?. J Nutr Health Aging 24, 1038–1039 (2020).', 'journal-title': 'J Nutr Health Aging'}, { 'key': '13920_CR52', 'doi-asserted-by': 'publisher', 'first-page': '688', 'DOI': '10.1093/ajcn/87.3.688', 'volume': '87', 'author': 'M Ilahi', 'year': '2008', 'unstructured': 'Ilahi, M., Armas, L. A. G. & Heaney, R. P. Pharmacokinetics of a single, ' 'large dose of cholecalciferol. Am. J. Clin. Nutr. 87, 688–691 (2008).', 'journal-title': 'Am. J. Clin. Nutr.'}, { 'key': '13920_CR53', 'doi-asserted-by': 'publisher', 'first-page': '377', 'DOI': '10.1016/j.jbi.2008.08.010', 'volume': '42', 'author': 'PA Harris', 'year': '2009', 'unstructured': 'Harris, P. A. et al. Research electronic data capture (REDCap)-A ' 'metadata-driven methodology and workflow process for providing ' 'translational research informatics support. J. Biomed. Inform. 42, ' '377–381 (2009).', 'journal-title': 'J. Biomed. Inform.'}, { 'key': '13920_CR54', 'doi-asserted-by': 'publisher', 'first-page': '259', 'DOI': '10.1016/j.jbi.2012.10.006', 'volume': '46', 'author': 'JS Obeid', 'year': '2013', 'unstructured': 'Obeid, J. S. et al. Procurement of shared data instruments for research ' 'electronic data capture (REDCap). J. Biomed. Inform. 46, 259–265 (2013).', 'journal-title': 'J. Biomed. Inform.'}, { 'key': '13920_CR55', 'unstructured': 'National Cancer Institute Division of Cancer Control & Population ' 'Services. Patient-Reported Outcomes version of the Common Terminology ' 'Criteria for Adverse Events (PRO-CTCAE). ' 'https://healthcaredelivery.cancer.gov/pro-ctcae/.'}, { 'key': '13920_CR56', 'doi-asserted-by': 'crossref', 'unstructured': 'CDC COVID-19 Response Team. Severe outcomes among patients with ' 'coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, ' '2020. Morbidity Mortality Week. Rep. 69, 343 (2020).', 'DOI': '10.15585/mmwr.mm6912e2'}, { 'key': '13920_CR57', 'doi-asserted-by': 'publisher', 'first-page': '401', 'DOI': '10.1053/j.jrn.2016.06.005', 'volume': '26', 'author': 'J Saldanha', 'year': '2016', 'unstructured': 'Saldanha, J. et al. Effects of resveratrol supplementation in nrf2 and ' 'NF-κB expressions in nondialyzed chronic kidney disease patients: A ' 'randomized, double-blind, placebo-controlled, crossover clinical trial. ' 'J. Ren. Nutr. 26, 401–406 (2016).', 'journal-title': 'J. Ren. Nutr.'}, { 'key': '13920_CR58', 'unstructured': 'R Core Team. R: A language and environment for statistical computing. (R ' 'Foundation for Statistical Computing, 2020).'}, { 'key': '13920_CR59', 'unstructured': 'StataCorp. Stata Statistical Software: Release 17. (2021).'}, { 'key': '13920_CR60', 'doi-asserted-by': 'publisher', 'first-page': '334', 'DOI': '10.1080/10543406.2019.1684308', 'volume': '30', 'author': 'I White', 'year': '2020', 'unstructured': 'White, I., Joseph, R. & Best, N. A causal modelling framework for ' 'reference-based imputation and tipping point analysis in clinical trials ' 'with quantitative outcome. J. Biopharm. Stat. 30, 334–350 (2020).', 'journal-title': 'J. Biopharm. Stat.'}, { 'key': '13920_CR61', 'doi-asserted-by': 'publisher', 'first-page': '9', 'DOI': '10.1111/j.1749-6632.2010.05842.x', 'volume': '1215', 'author': 'T Walle', 'year': '2011', 'unstructured': 'Walle, T. Bioavailability of resveratrol. Ann. N. Y. Acad. Sci. 1215, ' '9–15 (2011).', 'journal-title': 'Ann. N. Y. Acad. Sci.'}, { 'key': '13920_CR62', 'doi-asserted-by': 'publisher', 'first-page': '164', 'DOI': '10.3892/etm.2015.2895', 'volume': '11', 'author': 'C Sergides', 'year': '2016', 'unstructured': 'Sergides, C., Chirilă, M., Silvestro, L., Pitta, D. & Pittas, A. ' 'Bioavailability and safety study of resveratrol 500 mg tablets in ' 'healthy male and female volunteers. Exp. Ther. Med. 11, 164–170 (2016).', 'journal-title': 'Exp. Ther. Med.'}, { 'key': '13920_CR63', 'doi-asserted-by': 'publisher', 'first-page': '116', 'DOI': '10.1111/j.1399-6576.1997.tb04625.x', 'volume': '41', 'author': 'L Christrup', 'year': '1997', 'unstructured': 'Christrup, L. Morphine metabolites. Acta Anaesthesiol Scand. 41, 116–122 ' '(1997).', 'journal-title': 'Acta Anaesthesiol Scand.'}, { 'key': '13920_CR64', 'unstructured': 'Lauer, M. Continued Impact of COVID-19 on Biomedical Research. ' 'https://nexus.od.nih.gov/all/2020/11/04/continued-impact-of-covid-19-on-biomedical-research/ ' '(2020).'}, { 'key': '13920_CR65', 'unstructured': 'The Economist. Pandemic mortality - See how age and illnesses change the ' 'risk of dying from covid-19. ' 'https://www.economist.com/graphic-detail/covid-pandemic-mortality-risk-estimator ' '(2021).'}, { 'key': '13920_CR66', 'unstructured': 'Ohio Department of Health. COVID-19 Dashboard. ' 'https://coronavirus.ohio.gov/wps/portal/gov/covid-19/dashboards/overview ' '(2021).'}, { 'key': '13920_CR67', 'doi-asserted-by': 'publisher', 'first-page': '3693', 'DOI': '10.1111/febs.15495', 'volume': '287', 'author': 'E Merzon', 'year': '2020', 'unstructured': 'Merzon, E. et al. Low plasma 25(OH) vitamin D level is associated with ' 'increased risk of COVID-19 infection: An Israeli population-based study. ' 'FEBS J 287, 3693–3702 (2020).', 'journal-title': 'FEBS J'}, { 'key': '13920_CR68', 'unstructured': 'Centers for Disease Control and Prevention. Influenza Antiviral ' 'Medications: Clinician Summary. ' 'https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm ' '(2021).'}, { 'key': '13920_CR69', 'doi-asserted-by': 'publisher', 'first-page': '403', 'DOI': '10.1089/ars.2007.1926', 'volume': '10', 'author': 'A Bertelli', 'year': '2008', 'unstructured': 'Bertelli, A. et al. Analgesic resveratrol?. Antioxid. Redox Signal. 10, ' '403–404 (2008).', 'journal-title': 'Antioxid. Redox Signal.'}, { 'key': '13920_CR70', 'doi-asserted-by': 'publisher', 'first-page': '1591', 'DOI': '10.3389/fimmu.2021.670955', 'volume': '12', 'author': 'GA Rossi', 'year': '2021', 'unstructured': 'Rossi, G. A., Sacco, O., Capizzi, A. & Mastromarino, P. Can ' 'resveratrol-inhaled formulations be considered potential adjunct ' 'treatments for COVID-19?. Front. Immunol. 12, 1591 (2021).', 'journal-title': 'Front. Immunol.'}], 'container-title': 'Scientific Reports', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/s41598-022-13920-9.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-022-13920-9', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-022-13920-9.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 11, 25]], 'date-time': '2022-11-25T06:41:49Z', 'timestamp': 1669358509000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41598-022-13920-9'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 6, 29]]}, 'references-count': 70, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2022, 12]]}}, 'alternative-id': ['13920'], 'URL': 'http://dx.doi.org/10.1038/s41598-022-13920-9', 'relation': {}, 'ISSN': ['2045-2322'], 'subject': ['Multidisciplinary'], 'container-title-short': 'Sci Rep', 'published': {'date-parts': [[2022, 6, 29]]}, 'assertion': [ { 'value': '31 August 2021', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '30 May 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '29 June 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'The authors declare no competing interests.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '10978'}